Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, profitability has come under pressure as commoditized products face rapid price declines and limited differentiation.As a result, most generic manufacturers are leaning heavily on complex generics, injectables and biosimilars. These categories offer higher margins and, in many cases, limited-competition or exclusiv ...